Bethesda, MD (PRWEB) September 19, 2017
CME Outfitters, LLC, a leading accredited provider in continuing medical education, announces the launch of a new pair of CME Snacks (short online CME activities) discussing the newly approved biosimilar, infliximab, and its ability to treat a variety of inflammatory diseases. CME “Snacks” offer shorter, more focused content, allowing the viewer to have more control over the depth of content and time spent learning.
Biologic agents have been proven to be highly effective in treating inflammatory diseases such as rheumatoid arthritis (RA), adult ulcerative colitis (UC), psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and adult and pediatric Crohn’s disease (CD). Unfortunately, many health care plans restrict the use of these agents due to high cost.
Biosimilars are biopharmaceuticals that have been genetically engineered to be highly similar – meaning any difference is minor and not clinically meaningful - to an already existing approved biologic product. While biosimilars have been available in Europe since 2005, the first biosimilar monoclonal antibody in the United States, infliximab, has recently been approved for use in treating an array of inflammatory diseases.
The first activity, An Evolving Treatment Landscape for Inflammatory Disease: Involving Patients in the Discussion of Biosimilars, features Leonard H. Calabrese, DO, Russell D. Cohen, MD, FACG, AGAF, and Edward Li, PharmD, MPH, BCOP, as they discuss the differences between biosimilars and generic agents, costs, and reimbursement. This unique activity will highlight the voice of real patients with inflammatory diseases as they describe the education they have received on biosimilars from their clinicians.
The second CME Snack, An Evolving Treatment Landscape for Inflammatory Disease: The Role of Biosimilars in RA and IBD, with Drs. Calabrese and Cohen, will discuss the data, safety, and efficacy of agents approved for biosimilars in rheumatology and gastroenterology to treat rheumatoid arthritis and inflammatory bowel disease. Participants will learn how to best evaluate the safety and efficacy of emerging biosimilars for use in their practice as it relates to the treatment of inflammatory diseases.
CME Outfitters, LLC, has designated each of these enduring activities for a maximum of .5 AMA PRA Category 1 CreditTM.
This pair of CME Snacks, supported by an educational grant from Pfizer Inc., are a prelude to an upcoming Live CME Outfitters Webcast with Dr. Leonard Calabrese, where he will answer questions from participants of these CMEO Snacks while offering evidence, guidelines, and quality measures for collaborative strategies to optimally use biosimilars in patients with inflammatory diseases. The live Q&A will take place on Tuesday, October 10, 2017 from 12:00pm – 12:30pm ET. More information on this CME Outfitters Webcast, Debating Interchangeability, Efficacy, and Safety of Biosimilars in the Management of Inflammatory Disease, click here.
All of these activities and more can be found on CME Outfitters new Biosimilars Hub, which also hosts a variety of free downloadable resources clinicians can use in their practice to educate their patients. To visit the biosimilars hub, go to http://www.cmeoutfitters.com/BioSimHub.
About CME Outfitters, LLC
CME Outfitters develops and distributes live, recorded and web-based, outcomes- and evidence-based educational activities to thousands of clinicians each year and offers expert accreditation and outcome services for non-accredited organizations. CME Outfitters focuses on delivering education to specialty audiences, with strong expertise in neuroscience, inflammatory, infectious, and autoimmune diseases, and cardiovascular disease. For a complete list of certified activities and more information, visit http://www.cmeoutfitters.com or call 877.CME.PROS (877.263.7767).
“CME Outfitters …
Improving Clinical Behavior … One Change at a Time”